$2.6 Billion Worldwide Mesenchymal Stem Cells Industry to 2029 – by Product & Service, Type, Source of Isolation, Indication, Application and Region – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Mesenchymal Stem Cells Market Analysis by Product & Service, by Type, by Source of Isolation, by Indication, by Application by Region – Global Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering.

The mesenchymal stem cells market size is estimated to be USD 2.6 billion in 2021 and is expected to witness a CAGR of 14.12% during the forecast period 2022-2029.

Companies Mentioned

• Smith & Nephew (UK)
• MEDIPOST (South Korea)
• Anterogen (South Korea)
• CORESTEM (South Korea)
• PHARMICELL (South Korea)
• NuVasive (US)
• RTI Surgical (US)
• AlloSource (US)
• JCR Pharmaceuticals (Japan)
• Takeda Pharmaceutical Company (Japan)
• Holostem Terapie Avanzate S.r.l (Italy)
• Orthofix (US)
• Regrow Biosciences (India)
• Stempeutics Research (India)

The market is expected to grow due to increase in mesenchymal stem cell (MSC)-based research and its implications in the field of regenerative medicine. Other factors driving market expansion include changing environment of stem cell therapies. However, lack of standardization and regulation of delivery of stem cell system is expected to limit the market growth.

By Product & Service

Based on product & service, the market is bifurcated into products and services. In 2021, the product segment accounted for the highest revenue share due to a number of market players working to fill this market’s unexplored niches by launching a variety of projects including new product development and business growth.

By Type

On the basis of type, the market is divided into allogenic and autologous. In 2021, the allogenic segment accounted for the highest revenue share owing to the use of allogeneic mesenchymal stem cells in clinical settings has a good safety profile.

By Source of Isolation

Based on source of isolation, the market is segregated into peripheral blood, cancer, bone marrow, fetal liver, adipose tissues, fallopian tube, cord blood, and lung. In 2021, the bone marrow segment accounted for the highest revenue share due to the benefits such as these cells can develop into fibroblasts, fat, cardiac muscle cells, tendons, bones, cartilage, and endothelial cells and they have the capacity to differentiate into several other cell types, including fibroblasts and fat.

By Indications

On the basis of indications, the market is categorized into GvHD, liver diseases, cardiovascular disease, inflammatory and immunological diseases, bone and cartilage repair, and others. In 2021, the cardiovascular segment accounted for the highest revenue share owing to raising apoptosis resistance, encouraging myocardial cell differentiation, preventing fibrosis, lowering inflammation, and encouraging angiogenesis.

By Applications

Based on application, the market is segregated into tissue engineering, disease modeling, drug development & discovery, toxicology studies, stem cell banking, and others. In 2021, the diseases modeling segment accounted for the highest revenue share due to a growing number of studies that have employed mesenchymal stem cell models to investigate the underlying processes of chronic diseases.

Regional Markets

In 2021, the North America held the largest revenue share in the mesenchymal stem cells market in 2021, and it is predicted to continue to do so throughout the forecast period. The presence of major companies, the biopharmaceutical industry is increasing its R&D expenditure, and favourable regulatory changes are all driving to regional market growth.

For more information about this report visit https://www.researchandmarkets.com/r/l7dwg1

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900